MetLife enters its next reporting cycle with the Street upgrading price targets and short sellers quietly rebuilding positions — a combination that makes this week's price action worth watching closely.
The analyst tone has shifted firmly positive following Q1 results. Multiple firms raised targets this week. JP Morgan lifted its objective from $95 to $96, and Wells Fargo moved its target up from $90 to $95 — both maintaining Overweight ratings. Keefe, Bruyette & Woods made the largest move, raising its target to $98 from $87 while keeping an Outperform. The consensus mean now sits at $91, against a current price of $78.64, implying roughly 16% upside from here. Barclays also lifted its target to $93 earlier in the week following the earnings print. The mid-April noise — where BofA and Mizuho trimmed targets in the $90s range during the broader market dislocation — has been fully reversed by the post-earnings wave of upgrades.
The short interest story is more cautious than the analyst tone suggests. SI jumped 18% over the past week to 2.7% of free float — back near the April highs seen before the mid-month unwind. The move is notable: shorts had retreated sharply through late April and early May, with SI dropping from around 2.6% to a trough below 2.3% in the days surrounding the earnings release. The rebuild since May 11 is the fastest five-day accumulation in the 30-day window. Despite the increased positioning, the borrow market remains extremely comfortable. Cost to borrow is running at just 0.41% — well below the 0.56% level seen earlier in April — and availability is loose, meaning there is no squeeze pressure constraining new short positions. Availability has actually tightened slightly in this context, with utilisation at its 52-week high of 3.21%, but at those absolute levels it represents no meaningful friction.
Options positioning has drifted modestly more defensive. The put/call ratio ticked up to 1.48, slightly above its 20-day average of 1.42. The move is mild — just 0.6 standard deviations above the mean — and the 52-week range runs from 1.07 to 1.81, so the current reading is far from extreme. The options market is not signalling panic. It is reflecting a normal level of hedging activity for an insurer of this size heading into a mid-cycle stretch.
On valuation, MET trades at a P/E of around 7.7x, unchanged directionally over the past week, with a price-to-book of 1.69x — both multiples that have drifted modestly higher over the past month as the stock recovered from its April lows. The forward EPS growth factor ranks in the 91st percentile of the universe, a strong reading that supports the analyst community's conviction on earnings trajectory. The ORTEX short score has been climbing this week — from 32.9 at the start of May to 35.8 on May 12 — consistent with the uptick in estimated short interest, though the absolute level remains in the lower half of the historical range.
On the institutional side, Vanguard added nearly 7.8 million shares in the most recently reported quarter to push its stake above 11%. BlackRock added 1.5 million shares as recently as April 30. The accumulation by the two largest passive and active index managers is consistent with a stock gaining index weight rather than any active directional bet — but the direction is additive.
The next earnings event is on 16 June. Given the pattern of the past two prints — where MET fell roughly 2.6% and 1.4% respectively in the session following results — and the rebuilding short interest, the set-up heading into that date is the obvious thing to track from here. Peer LNC fell 6.5% on the week while PRU managed a 2.3% gain — illustrating that the insurance sector is trading with notable dispersion right now, and MET's relative resilience (down just 1.6% on the week) sits somewhere in the middle of that range.
Overall, positioning looks mildly cautious rather than aggressively bearish: the Street is lifting targets and the stock screens cheaply, but short sellers have returned quickly after earnings, and the options market carries a slight defensive tilt heading toward mid-June.
See the live data behind this article on ORTEX.
Open MET on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
